Coleman RL, et al. - Researchers focused on the overall influence of alpha-glucosidase inhibitors (AGIs) regarding incident type 2 diabetes in people with impaired glucose tolerance (IGT), and cardiovascular (CV) consequences in those with IGT or type 2 diabetes. They selected randomized controlled trials from PubMed and SCOPUS, wherein, AGIs were compared with placebo in people with IGT or type 2 diabetes, with or without established CV disease, describing the incidence of type 2 diabetes and/or CV results. Involving ≥ 500 participants and/or having ≥ 100 endpoints of interest were eligibility criteria for studies. They identified 10 trials, of those, three satisfied the inclusion criteria for incident type 2 diabetes and four were eligible for CV results. Findings revealed a significant decrease in the risk of incident type 2 diabetes by 23% as a result of allocating individuals with IGT to an AGI, whereas a neutral influence on CV results was reported in those with IGT or type 2 diabetes.